Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases

Paul Zarogoulidis; Panos Chinelis; Anastasia Athanasiadou; Theodora Tsiouda; Georgia Trakada; Anastasios Kallianos; Lemonia Veletza; Dimitris Hatzibougias; Electra Mihalopoulou; Eirini Goupou; Christoforos Kosmidis; Chrysanthi Sardeli; Haidong Huang; Wolfgang Hohenforst-Schmidt

doi:10.1016/j.rmcr.2017.07.004

Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases

Respir Med Case Rep. 2017 Jul 14:22:101-105. doi: 10.1016/j.rmcr.2017.07.004. eCollection 2017.

Authors

Affiliations

¹ Pulmonary Department-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
² Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.
⁴ Microdiagnostics, Pathology Private Center, Thessaloniki, Greece.
⁵ Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece.
⁶ Pharmacology-Clinical Pharmacology, Department of Clinical, Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁷ Department of Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
⁸ Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.

Abstract

In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.

Keywords: Adenocarcinoma; Colitis; Immunotherapy; NSCLC; Nivolumab; Pericarditis; Pneumonitis.

Publication types

Case Reports